A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease
Status:
Completed
Trial end date:
2009-08-20
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and tolerability of afegostat tartrate in participants with
type 1 Gaucher disease who were not receiving enzyme replacement therapy (ERT) or substrate
reduction therapy (SRT).